Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hypertonic sodium chloride solution (3%) increases extracellular osmolarity, drawing water from intracellular space into extracellular compartment via osmotic gradient, thereby reducing cerebral edema and intracranial pressure. Sodium ions also restore electrolyte balance in hyponatremia.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Management of symptomatic hyponatremia (e.g., severe hyponatremia with neurological symptoms),Reduction of intracranial pressure in cerebral edema (off-label, but commonly used),Hypovolemia and hyponatremia due to salt depletion (off-label use)
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Intravenous infusion of 3% sodium chloride at a rate of 1-2 m L/kg/hour, with a typical rate of 50-100 m L/hour for adults, titrated to serum sodium goals. Maximum infusion rate: 100 m L/hour, with careful monitoring of serum sodium (increase not >8-10 m Eq/L per 24 hours).
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Not applicable: sodium and chloride are endogenous electrolytes; administered dose mixes with body pools and is eliminated via renal excretion with a half-life dependent on renal function and hydration status. In euvolemic individuals with normal renal function, the terminal elimination half-life of excess sodium is approximately 6–12 hours.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Sodium chloride is not metabolized; it is distributed in extracellular fluid and excreted primarily by the kidneys. No hepatic metabolism.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Renal (essentially 100%): sodium and chloride ions are excreted unchanged in urine. No biliary or fecal elimination of intact drug; sodium and chloride are obligately filtered and variably reabsorbed based on volume status and renal function.
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
0%: sodium and chloride ions are not protein bound.
Low protein binding; 0–11% bound, primarily to albumin.
Total body water (0.6 L/kg): sodium distributes primarily in extracellular fluid (0.2 L/kg); chloride distributes similarly. Clinical meaning: reflects rapid equilibration with the extracellular space.
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Intravenous: 100% (bioequivalent to endogenous electrolytes). No oral or other relevant routes for hypertonic saline; oral administration would have variable absorption and is not used.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
No specific dose adjustment for renal impairment based on GFR. Use with caution in patients with renal failure due to risk of fluid overload and hypernatremia. Monitor renal function and fluid balance closely.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No specific dose adjustment for hepatic impairment based on Child-Pugh score. Use with caution in patients with cirrhosis due to risk of ascites and fluid overload. Monitor serum sodium and fluid status.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Intravenous 3% sodium chloride: 0.5-1 m L/kg over 30-60 minutes, with a maximum rate of 1 m L/kg/hour, titrated to serum sodium. Typical dose for severe hyponatremia: 1-2 m L/kg/hour. Monitor serum sodium every 1-2 hours.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Lower initial infusion rates (e.g., 25-50 m L/hour) due to decreased renal function and higher risk of fluid overload. More frequent monitoring of serum sodium and hemodynamic status. Avoid rapid correction (>8 m Eq/L per 24 hours).
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
None
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Risk of osmotic demyelination syndrome (central pontine myelinolysis) if serum sodium is corrected too rapidly; use with caution in patients with heart failure, renal impairment, or pre-existing hypernatremia; monitor serum sodium, chloride, and fluid status; avoid extravasation as it may cause tissue necrosis.
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hypernatremia; fluid overload; severe renal impairment with oliguria or anuria; pre-existing hyperchloremia; concurrent use of medications that cause sodium retention (e.g., corticosteroids) should be considered relative contraindication; not for use as a maintenance fluid.
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No direct food interactions. However, dietary sodium restriction is typically indicated in hyponatremia management, but not during active treatment with 3% saline.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
Sodium chloride 3% is a hypertonic solution used intravenously for correction of severe hyponatremia. In pregnancy, no teratogenic effects have been reported; however, rapid correction of hyponatremia can cause osmotic demyelination syndrome, which may affect both mother and fetus. First trimester: no known teratogenic risk. Second and third trimesters: cautious use indicated as maternal fluid and electrolyte imbalances can impact fetal homeostasis.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Sodium chloride is a normal constituent of breast milk. Intravenous infusion of hypertonic saline may transiently increase maternal serum sodium, but negligible transfer into milk is expected. M/P ratio not established. Generally considered compatible with breastfeeding, but monitor infant for signs of electrolyte imbalance if maternal therapy is prolonged or high-dose.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Pregnancy does not typically require dose adjustment of hypertonic saline. However, pregnancy-associated plasma volume expansion and altered renal function may influence sodium handling; monitor serum sodium levels frequently. Use with caution in preeclampsia due to increased risk of fluid overload.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
Hypertonic saline (3%) is used for rapid correction of symptomatic hyponatremia (e.g., seizures, coma). Infuse via central line to avoid phlebitis; use an infusion pump. Monitor serum sodium every 2-4 hours; do not exceed 8-12 m Eq/L rise in 24 hours to prevent osmotic demyelination. Reserve for ICU setting.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
This medication is given intravenously to raise low sodium levels.,You will have frequent blood tests to monitor your sodium levels.,Report any new headache, confusion, or muscle weakness immediately.,Do not stop the infusion or adjust the rate on your own.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM CHLORIDE 3% IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER is a Electrolyte that works by Hypertonic sodium chloride solution (3%) increases extracellular osmolarity, drawing water from intracellular space into extracellular compartment via osmotic gradient, thereby reducing cerebral edema and intracranial pressure. Sodium ions also restore electrolyte balance in hyponatremia.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM CHLORIDE 3% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM CHLORIDE 3% IN PLASTIC CONTAINER is: Intravenous infusion of 3% sodium chloride at a rate of 1-2 m L/kg/hour, with a typical rate of 50-100 m L/hour for adults, titrated to serum sodium goals. Maximum infusion rate: 100 m L/hour, with careful monitoring of serum sodium (increase not >8-10 m Eq/L per 24 hours).. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining SODIUM CHLORIDE 3% IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. SODIUM CHLORIDE 3% IN PLASTIC CONTAINER is classified as Category A/B. Sodium chloride 3% is a hypertonic solution used intravenously for correction of severe hyponatremia. In pregnancy, no teratogenic effects have been reported; however, rapid correc. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.